Skip to content

The Burden of Access in Duchenne Muscular Dystrophy in the US

The Burden of Access in Duchenne Muscular Dystrophy in the US. A Qualitative Assessment of the Impact of Access on the Lives of Families Affected by DMD and Their Healthcare Providers.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03951675
Enrollment
57
Registered
2019-05-15
Start date
2019-06-18
Completion date
2020-05-28
Last updated
2020-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duchenne Muscular Dystrophy

Brief summary

This study is being conducted to determine if DMD patients / families and healthcare providers experience burdens related to access, and if so, to identify them, and to determine life impacts to the patient, if any, of these burdens. Data from healthcare providers will be collected by an online survey and from patients/families by one on one telephone interview.

Detailed description

Patient/Parent Portion In this non-interventional study, DMD patients / parents of DMD patients will be interviewed to gather qualitative input, in the patient's voice, regarding challenges associated with access to medications, services and medical equipment, and how these burdens impact quality of life. Healthcare Provider Portion In this non-interventional study, healthcare providers who see patients with DMD and who deal with insurance issues on behalf of DMD patients will participate in an online survey designed to determine the burden associated with access to medications, services and medical equipment.

Interventions

None listed

Sponsors

Engage Health Inc.
CollaboratorINDUSTRY
University of Florida
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

Patient/Parent interviews * Patients residing in the US who have been diagnosed with DMD who are age 18 years or older, or the parent / legal guardian of a person of any age who has been diagnosed with DMD, * Have provide Proof of DMD to ensure that they are impacted by the disease, * Who have provided sufficient information in the RSVP process to determine their functional status; ambulatory, transitional or non-ambulatory, * State that they are the person who deals with insurance issues for the affected patient and, * Who are able to understand and consent to participation in the study Healthcare Provider survey * Healthcare providers (physicians, nurse practitioners, and physician assistants) currently involved in the care of patients with DMD * Are currently practicing in the US, * Who have provided sufficient information in the survey screening to determine that they currently care for DMD patients, * State that they and/or persons on their staff interface with insurance companies for DMD patients related to access to medications, services and/or medical equipment and, * Who are able to understand and consent to participation in the study

Exclusion criteria

* There are no stated

Design outcomes

Primary

MeasureTime frameDescription
Burden frequency by functional categoryOver 12 monthsThe frequency that each burden is mentioned by a patient according to their functional category as measured by the VIGNOS scale. This is the number of times each burden is mentioned by a patient during their interview, assessed by each functional category.

Secondary

MeasureTime frameDescription
Burden frequency by type of insuranceOver 12 monthsThe frequency that each burden is mentioned by a patient according to their insurance coverage. This is the number of times each burden is mentioned by a patient during their interview, assessed by each type of insurance.
Life impact frequency by functional categoryOver 12 monthsThe frequency that each life impact is mentioned by a patient according to their functional category as measured by the VIGNOS scale. This is the number of times each life impact is mentioned by a patient during their interview, assessed by each functional category.
Life impact frequency by type of insuranceOver 12 monthsThe frequency that each life impact is mentioned by a patient according to their insurance coverage. The number of times each life impact is mentioned by a patient during their interview, assessed by each type of insurance.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026